The life-threatening eruptions of immune checkpoint inhibitor therapy
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Clinics in Dermatology
- Vol. 38 (1) , 94-104
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NIH Blueprint for Neuroscience Research (P30CA016359)
- National Cancer Institute
This publication has 61 references indexed in Scilit:
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline SummaryJournal of Oncology Practice, 2018
- Dermatologic Reactions to Immune Checkpoint InhibitorsAmerican Journal of Clinical Dermatology, 2017
- Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective studyEuropean Journal Of Dermatology, 2017
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaJournal of Hepatology, 2017
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapyJournal of Cutaneous Pathology, 2016
- Ipilimumab in patients with cancer and the management of dermatologic adverse eventsJournal of the American Academy of Dermatology, 2014
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyThe Lancet Oncology, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009